Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001303454 | SCV001492701 | uncertain significance | not provided | 2024-01-08 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 39 of the IFNAR1 protein (p.Asp39Asn). This variant is present in population databases (rs148989381, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with IFNAR1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1006414). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV001303454 | SCV005050782 | likely benign | not provided | 2024-05-01 | criteria provided, single submitter | clinical testing | IFNAR1: BP4, BS1:Supporting |
Breakthrough Genomics, |
RCV001303454 | SCV005195114 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003963202 | SCV004778602 | likely benign | IFNAR1-related disorder | 2023-02-28 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |